Literature DB >> 9951954

Long-acting isosorbide mononitrate.

A Prakash1, A Markham.   

Abstract

Elantan long (EL) is the only long-acting isosorbide mononitrate formulation based on a controlled membrane principle. 30% of the dose is available for immediate release and the remaining 70% is gradually released over time. After oral administration, isosorbide mononitrate EL has a quick onset of action (30 minutes) and effects are evident for up to 17 hours. The antianginal effects of once-daily isosorbide mononitrate EL 50 to 100mg were generally similar to those of conventional isosorbide mononitrate or isosorbide dinitrate 10 to 20mg twice or 3 times daily, or sustained-release nifedipine 20mg twice or 3 times daily. Patients tended to show a better response with once-daily isosorbide mononitrate EL 50mg than with bupranolol 100mg. Patients showed significantly greater improvement in some quality-of-life indices with once-daily isosorbide mononitrate EL than with twice or 3 times daily regimens of conventional isosorbide mononitrate or isosorbide dinitrate. Tolerance did not develop after 13 months of once-daily administration of isosorbide mononitrate EL. No rebound increase in incidence of ischaemic episodes was observed after discontinuation of the drug.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9951954     DOI: 10.2165/00003495-199957010-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  17 in total

1.  Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris.

Authors:  R Bonn
Journal:  Am J Cardiol       Date:  1988-03-25       Impact factor: 2.778

2.  The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.

Authors:  A H Thomson; S H Miller; S T Green; B Whiting
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Long-acting, marked antiischemic effect maintained unattenuated during long-term interval treatment with once-daily isosorbide-5-mononitrate in sustained-release form.

Authors:  A Beyerle; G Reiniger; W Rudolph
Journal:  Am J Cardiol       Date:  1990-06-15       Impact factor: 2.778

4.  Antianginal efficacy and tolerability of 50 mg sustained-release isosorbide 5-mononitrate in an open twelve-month observation study.

Authors:  W Heepe; U Gathmann-Lewik
Journal:  Cardiology       Date:  1987       Impact factor: 1.869

5.  Evaluation of the antianginal and anti-ischemic efficacy of slow-release isosorbide-5-mononitrate capsules, bupranolol and their combination, in patients with chronic stable angina pectoris.

Authors:  H P Krepp
Journal:  Cardiology       Date:  1991       Impact factor: 1.869

6.  Sustained-release IS-5-MN in the treatment of coronary heart disease.

Authors:  M Keck
Journal:  Cardiology       Date:  1991       Impact factor: 1.869

7.  Dose-effect relationship amongst three different sustained-release forms of isosorbide 5-mononitrate in patients with coronary artery disease.

Authors:  P Kenedi; U Gathmann-Lewik
Journal:  Cardiology       Date:  1987       Impact factor: 1.869

8.  Slow-release isosorbide-5-mononitrate--a new once daily therapeutic modality for angina pectoris.

Authors:  M Ahmadinejad; B Eghbal; W Sorgenicht; A Schneeweiss; M Weiss
Journal:  Eur Heart J       Date:  1988-01       Impact factor: 29.983

9.  Isosorbide-5-mononitrate and nifedipine can reduce ischaemic ST-segment changes during Holter monitoring in patients with spontaneous angina pectoris.

Authors:  T von Arnim; A Erath; E Reuschel-Janetschek
Journal:  Eur Heart J       Date:  1988-01       Impact factor: 29.983

10.  Anti-ischemic effects of slow-release formulations of nifedipine, isosorbide-5-mononitrate and their combination in patients with coronary heart disease.

Authors:  H H Erlemeier; W Kupper; N B Hempel; W Bleifeld
Journal:  Cardiology       Date:  1988       Impact factor: 1.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.